Form 8-K - Current report:
SEC Accession No. 0001664710-26-000036
Filing Date
2026-06-25
Accepted
2026-06-25 16:02:15
Documents
12
Period of Report
2026-06-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20260623.htm   iXBRL 8-K 43754
2 EX-99.1 exhibit99162526pr.htm EX-99.1 10051
  Complete submission text file 0001664710-26-000036.txt   178114

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20260623.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20260623_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20260623_pre.xml EX-101.PRE 13046
15 EXTRACTED XBRL INSTANCE DOCUMENT kros-20260623_htm.xml XML 2823
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 261121842
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)